CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer

Bookmark and Share
Published: 29 Sep 2019
Views: 454
Rating:
Save
Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California

Prof Dennis Slamon presents data from the MONALEESA-3 trial during a press conference at the 2019 ESMO congress.

This was a trial looking at treatment with the CDK4/6 inhibitor ribociclib plus fulvestrant in postmenopausal patients with HR HER2- advanced breast cancer.

Watch Prof Slamon's interview with ecancer here.

Read more on this study here.